

## Opto Circuits registers strong growth in revenues in Q3FY14

Bengaluru, India | 17<sup>th</sup> February 2013:

Opto Circuits (India) Ltd., a leading developer and manufacturer of medical equipment and interventional devices for the global markets, today announced its financial results for the second quarter ending December 31<sup>st</sup>, 2013.

### Performance Highlight

	Quarterly		
	Q3FY14	Q2FY14	Growth
	Rs. Cr	Rs. Cr	(%)
Net Sales	354.3	370.0	(4.2)
EBITDA	59.2	101.7	(41.8)
Net Profit	(6.8)	44.0	(115.4)
<b>Segment Contribution</b>			
Medical Equipment & Consumables [Non Invasive]	249	297	(16.3)
Interventional Devices & Tools [Invasive]	104	71	46.3
Non Medical	1	2	(14.7)

**NSE Symbol:** OPTOCIRCU  
**BSE Code:** 532391

**Headquarters:**  
Bengaluru, Karnataka, India

**Industry:** Medical Technology

**Key Products:** AEDs, Patient Monitors, Cardiac Monitors, Vascular Diagnostics, Angioplasty Devices

- FY2013 -

**Consolidated Financials:**  
Net Sales - Rs. 2397 crs  
Net Profit - Rs. 379 crs  
EPS - Rs. 15.67

### Management Comment:

There have been disruptions in our Vizag SEZ, logistically due to political circumstances there. We have had to streamline our supplies from our overseas entities in Malaysia and USA to meet customer requirements.

This has resulted in reduced turnover and margins this quarter. The situation is being addressed on a long term basis by manufacturing out of Malaysia and USA.

### Other key highlights in Q3FY14:

#### Medical Equipment and Consumables: (Non Invasive)

##### Cardiac Science (CSC)

- Participated in Medica (one of the largest trade shows for the health care industry) 2013. Booth was very busy and lot of interest shown for G5

### Unetixs Vascular Inc

- Unetixs Vascular Inc., a group company of Opto Circuits (India) Ltd., and a leader in non-invasive vascular technology, have completed 25 years since its inception. The company commemorated its milestone anniversary by hosting Rhode Island Gov. Lincoln Chafee, Michael Fine, Director of Department Health, and other state leaders at the company's facility on October 28. They appreciated the facilities and our cutting edge vascular testing equipments.
- Participated in Medica (one of the largest trade shows for the health care industry) 2013.

### Interventional Devices and Tools: (Invasive)

#### Eurocor

- During the quarter, we came out with 6 and 12 months insights of the ongoing Freeway Stent study at Eurocor in the TCT Congress in San Francisco. The test results were positive and it was observed that performance of our drug coated balloon - freeway has improved because of the DCB platform. This Freeway Stent Study will offer better treatment options and significant therapeutic advantages for the patients.”
- Eurocor received the registration approval for its Genius Magic CC, DIOR, Freeway 014/035, Genius Taxcor I for Kazakhstan.

For More Information please check Opto Blog - <http://blog.optoindia.com/>

### About: Opto Circuits (India) Ltd.

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Mediaid](#), [AMD L](#) and [Unetixs Vascular](#) are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developing economies. We've been ranked in Forbes' *Asia's 200 Best under a Billion* lists in 2008, 2009 and 2011. For information, please visit [www.optoindia.com](http://www.optoindia.com).

#### Contact:

OCI: Media Queries: [media@optoindia.com](mailto:media@optoindia.com) | Investor Queries | [ir@optoindia.com](mailto:ir@optoindia.com) | +91 080- 28521040-42

Adfactors PR: Neha Goenka: [neha.goenka@adfactorspr.com](mailto:neha.goenka@adfactorspr.com) | +91 22 6757 4332

*Disclaimer: Statements made in this document describing the company's objectives, projections, estimates, expectations may be "Forward-looking Statements" within the meaning of all applicable securities' laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates changes in government regulations, tax laws, other statutes and other incidental factors.*